Lifestyle Modifications and Nutritional and Therapeutic Interventions in Delaying the Progression of Chronic Kidney Disease: A Review

被引:18
|
作者
Alkhatib, Lean [1 ]
Diaz, Lorena A. Velez [2 ]
Varma, Samyukta [3 ]
Chowdhary, Arsh [4 ]
Bapat, Prachi [5 ]
Pan, Hai [6 ]
Kukreja, Geetika [7 ]
Palabindela, Prasannalaxmi [8 ]
Selvam, Sri Abirami [9 ]
Kalra, Kartik [10 ]
机构
[1] Royal Med Serv, Internal Med, Amman, Jordan
[2] Univ Guayaquil, Med, Guayaquil, Ecuador
[3] Madurai Med Coll, Internal Med, Madurai, India
[4] Smt Kashibai Navale Med Coll & Gen Hosp, Nephrol, Pune, India
[5] Smt Kashibai Navale Med Coll & Gen Hosp, Gen Med, Pune, India
[6] Tianjin Univ Chinese Med, Pathol, Tianjin, Peoples R China
[7] Henry Ford Hlth Syst, Internal Med & Hematol Oncol, Clinton Township, MI USA
[8] Jennie Stuart Hlth, Internal Med, Hopkinsville, KY USA
[9] St Mary Hosp, Internal Med, Langhorne, PA USA
[10] Geisinger Med Ctr, Nephrol, Danville, VA USA
关键词
treatment options for diabetic nephropathy; diabetic kidney disease (dkd); chronic kidney disease (ckd); ckd progression; ckd management; CARDIOVASCULAR RISK; SGLT2; INHIBITORS; HYPERTENSION; ASSOCIATION; FINERENONE; MANAGEMENT; OUTCOMES;
D O I
10.7759/cureus.34572
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic kidney disease (CKD) is a debilitating progressive illness that affects more than 10% of the world's population. In this literature review, we discussed the roles of nutritional interventions, lifestyle modifications, hypertension (HTN) and diabetes mellitus (DM) control, and medications in delaying the progression of CKD. Walking, weight loss, low-protein diet (LPD), adherence to the alternate Mediterranean (aMed) diet, and Alternative Healthy Eating Index (AHEI)-2010 slow the progression of CKD. However, smoking and binge alcohol drinking increase the risk of CKD progression. In addition, hyperglycemia, altered lipid metabolism, low-grade inflammation, over-activation of the renin-angiotensin-aldosterone system (RAAS), and overhydration (OH) increase diabetic CKD progression. The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend blood pressure (BP) control of <140/90 mmHg in patients without albuminuria and <130/80 mmHg in patients with albuminuria to prevent CKD progression. Medical therapies aim to target epigenetic alterations, fibrosis, and inflammation. Currently, RAAS blockade, sodium-glucose cotransporter-2 (SGLT2) inhibitors, pentoxifylline, and finerenone are approved for managing CKD. In addition, according to the completed Study of Diabetic Nephropathy with Atrasentan (SONAR), atrasentan, an endothelin receptor antagonist (ERA), decreased the risk of renal events in diabetic CKD patients. However, ongoing trials are studying the role of other agents in slowing the progression of CKD.
引用
收藏
页数:10
相关论文
共 50 条
  • [22] Interventions To Attenuate Vascular Calcification Progression in Chronic Kidney Disease: A Systematic Review of Clinical Trials
    Xu, Chelsea
    Smith, Edward R.
    Tiong, Mark K.
    Ruderman, Irene
    Toussaint, Nigel D.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (05): : 1011 - 1032
  • [23] Sarcopenia in Chronic Kidney Disease: Factors, Mechanisms, and Therapeutic Interventions
    Watanabe, Hiroshi
    Enoki, Yuki
    Maruyama, Toru
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2019, 42 (09) : 1437 - 1445
  • [24] Slowing the progression of adult chronic kidney disease - Therapeutic advances
    Taal, MW
    DRUGS, 2004, 64 (20) : 2273 - 2289
  • [25] Fruit for thought: lifestyle interventions to reduce the risk of future chronic kidney disease
    Lees, Jennifer S.
    Mark, Patrick B.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36 (06) : 963 - 965
  • [26] Traditional and Novel Dietary Interventions for Preventing Progression of Chronic Kidney Disease
    Kovesdy, Csaba P.
    JOURNAL OF RENAL NUTRITION, 2013, 23 (03) : 241 - 245
  • [27] Metformin for preventing the progression of chronic kidney disease (Review)
    El-Damanawi, Ragada
    Stanley, Isabelle Kitty
    Staatz, Christine
    Pascoe, Elaine M.
    Craig, Jonathan C.
    Johnson, David W.
    Mallett, Andrew J.
    Hawley, Carmel M.
    Milanzi, Elasma
    Hiemstra, Thomas F.
    Viecelli, Andrea K.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2024, (06):
  • [28] Febuxostat is superior to allopurinol in delaying the progression of renal impairment in patients with chronic kidney disease and hyperuricemia
    Xin Zhang
    Dapeng Wan
    Guosheng Yang
    Qingping Peng
    Xiaohui Wang
    International Urology and Nephrology, 2019, 51 : 2273 - 2283
  • [29] Febuxostat is superior to allopurinol in delaying the progression of renal impairment in patients with chronic kidney disease and hyperuricemia
    Zhang, Xin
    Wan, Dapeng
    Yang, Guosheng
    Peng, Qingping
    Wang, Xiaohui
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2019, 51 (12) : 2273 - 2283
  • [30] EFFECT OF STATINS IN DELAYING THE PROGRESSION OF DIABETIC KIDNEY DISEASE: SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS
    Mohanty, M.
    Thakker, D.
    Gor, D.
    Raval, A.
    VALUE IN HEALTH, 2013, 16 (03) : A171 - A171